share_log

Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

齊默生物力（紐約證交所代碼：ZBH）公佈季度收益業績，超過預期 0.05 美元每股盈利
kopsource ·  2023/02/05 10:41

Zimmer Biomet (NYSE:ZBH – Get Rating) announced its earnings results on Friday. The medical equipment provider reported $1.88 EPS for the quarter, beating the consensus estimate of $1.83 by $0.05, Briefing.com reports. The company had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.76 billion. Zimmer Biomet had a return on equity of 11.92% and a net margin of 3.89%. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.95 EPS. Zimmer Biomet updated its FY 2023 guidance to $6.95-$7.15 EPS and its FY23 guidance to $6.95-7.15 EPS.

Zimmer Biomet(紐約證券交易所代碼：ZBH-GET Rating)週五公佈了收益結果。據Briefing.com報道，這家醫療設備提供商公佈本季度每股收益為1.88美元，比普遍預期的1.83美元高出0.05美元。該公司本季度營收為18.3億美元，而分析師預期為17.6億美元。Zimmer Biomet的股本回報率為11.92%，淨利潤率為3.89%。與去年同期相比，該公司本季度的收入增長了2.7%。去年同期，該公司每股收益為1.95美元。Zimmer Biomet將其2023財年每股收益指引更新為6.95-7.15美元，將23財年指引更新為6.95-7.15美元每股收益。

Zimmer Biomet Trading Up 1.6 %

Zimmer Biomet交易上漲1.6%

Shares of ZBH traded up $2.04 during mid-day trading on Friday, hitting $129.45. The company had a trading volume of 2,854,132 shares, compared to its average volume of 1,754,061. The business's 50-day simple moving average is $125.21 and its 200-day simple moving average is $115.79. The company has a quick ratio of 1.05, a current ratio of 1.98 and a debt-to-equity ratio of 0.41. Zimmer Biomet has a 1-year low of $100.39 and a 1-year high of $135.05. The stock has a market cap of $27.17 billion, a PE ratio of 117.68, a P/E/G ratio of 2.43 and a beta of 1.02.

在週五的午盤交易中，ZBH的股價上漲了2.0美元，達到129.45美元。該公司的成交量為2854,132股，而其平均成交量為1,754,061股。該業務的50日簡單移動均線切入位在125.21美元，200日簡單移動均線切入位在115.79美元。該公司的速動比率為1.05，流動比率為1.98，債務權益比率為0.41。Zimmer Biomet的一年低點為100.39美元，一年高位為135.05美元。該股市值271.7億美元，市盈率117.68，市盈率2.43，貝塔係數1.02。

Get
到達
Zimmer Biomet
Zimmer Biomet
alerts:
警報：

Zimmer Biomet Announces Dividend

Zimmer Biomet宣佈分紅

The company also recently declared a quarterly dividend, which was paid on Tuesday, January 31st. Stockholders of record on Tuesday, December 27th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Friday, December 23rd. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.74%. Zimmer Biomet's dividend payout ratio (DPR) is presently 87.27%.

該公司最近還宣佈了季度股息，股息於1月31日(星期二)支付。12月27日(星期二)登記在冊的股東獲得了每股0.24美元的股息。本次股息除息日期為12月23日(星期五)。這意味着年化股息為0.96美元，股息收益率為0.74%。Zimmer Biomet的股息支付率(DPR)目前為87.27%。

Analyst Ratings Changes

分析師評級發生變化

A number of analysts recently commented on the company. Wells Fargo & Company raised Zimmer Biomet from an "underweight" rating to an "equal weight" rating and increased their price target for the company from $116.00 to $124.00 in a research report on Wednesday, November 23rd. Barclays began coverage on Zimmer Biomet in a research report on Monday, October 17th. They issued an "underweight" rating and a $104.00 price target on the stock. StockNews.com assumed coverage on shares of Zimmer Biomet in a research note on Wednesday, October 12th. They set a "buy" rating for the company. Evercore ISI downgraded shares of Zimmer Biomet from an "outperform" rating to an "inline" rating and set a $130.00 target price for the company. in a report on Tuesday, January 3rd. Finally, Jefferies Financial Group began coverage on shares of Zimmer Biomet in a report on Wednesday, October 12th. They issued an "underperform" rating and a $95.00 price target for the company. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $129.05.
一些分析師最近對該公司發表了評論。富國銀行週三在一份研究報告中將齊默爾生物科技公司的評級從“減持”上調至“持平”，並將該公司的目標價從116.00美元上調至124.00美元。巴克萊在10月17日星期一的一份研究報告中開始報道Zimmer Biomet。他們對該股給予了“減持”評級和104.00美元的目標價。StockNews.com在10月12日星期三的一份研究報告中對Zimmer Biomet的股票進行了報道。他們為該公司設定了“買入”評級。Evercore ISI將齊默生物科技的股票評級從表現優於大盤下調至內聯評級，併為該公司設定了130.00美元的目標價。在1月3日星期二的一份報告中。最後，傑富瑞金融集團在10月12日星期三的一份報告中開始報道Zimmer Biomet的股票。他們對該公司的評級為“表現不佳”，目標價為95.00美元。三名投資分析師對該股的評級為賣出，九名分析師給出了持有評級，七名分析師給出了該公司的買入評級。根據MarketBeat.com的數據，該公司目前的平均評級為持有，共識目標價為129.05美元。

Institutional Inflows and Outflows

機構資金流入和流出

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBH. Aviva PLC raised its holdings in shares of Zimmer Biomet by 0.4% during the first quarter. Aviva PLC now owns 30,636 shares of the medical equipment provider's stock worth $3,918,000 after purchasing an additional 137 shares during the period. Parkside Financial Bank & Trust lifted its stake in Zimmer Biomet by 19.1% during the first quarter. Parkside Financial Bank & Trust now owns 1,212 shares of the medical equipment provider's stock valued at $155,000 after buying an additional 194 shares in the last quarter. Retirement Systems of Alabama lifted its position in shares of Zimmer Biomet by 0.3% in the third quarter. Retirement Systems of Alabama now owns 69,691 shares of the medical equipment provider's stock worth $7,286,000 after purchasing an additional 213 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Zimmer Biomet by 0.4% in the third quarter. Captrust Financial Advisors now owns 52,848 shares of the medical equipment provider's stock worth $5,525,000 after purchasing an additional 232 shares in the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund increased its holdings in Zimmer Biomet by 5.0% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 7,519 shares of the medical equipment provider's stock worth $786,000 after buying an additional 359 shares during the last quarter. 87.21% of the stock is owned by institutional investors and hedge funds.

一些對衝基金和其他機構投資者最近買賣了ZBH的股票。英傑華在第一季度增持了Zimmer Biomet的股票0.4%。英傑華目前持有30,636股這家醫療設備提供商的股票，價值391.8萬美元，在此期間又購買了137股。Parkside Financial Bank&Trust在第一季度增持了Zimmer Biomet 19.1%的股份。Parkside Financial Bank&Trust現在擁有1212股這家醫療設備提供商的股票，價值15.5萬美元，上個季度又購買了194股。阿拉巴馬州的退休系統公司在第三季度將其在Zimmer Biomet股票的頭寸提高了0.3%。阿拉巴馬州的退休系統公司在上個季度又購買了213股後，現在擁有69,691股這家醫療設備提供商的股票，價值7,286,000美元。CapTrust Financial Advisors在第三季度將其在Zimmer Biomet股票的頭寸提高了0.4%。CapTrust Financial Advisors現在擁有這家醫療設備提供商52,848股股票，價值5,525,000美元，上個季度又購買了232股。最後，肯塔基州退休系統保險信託基金在第三季度增持了Zimmer Biomet 5.0%的股份。肯塔基州退休系統保險信託基金現在擁有這家醫療設備提供商7519股股票，價值78.6萬美元，此前在上個季度又購買了359股。87.21%的股票由機構投資者和對衝基金持有。

About Zimmer Biomet

關於Zimmer Biomet

(Get Rating)

(獲取評級)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.

齊默爾生物科技控股公司從事整形外科重建產品的設計、製造和營銷。該公司還提供運動醫學、生物製品、四肢和創傷產品、脊柱、顱頜面部和胸部產品、基於辦公室的技術、牙科植入物和相關外科產品。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Zimmer Biomet (ZBH)
  • MarketBeat Week in Review – 1/30 – 2/3
  • Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
  • Zimmer Biomet Beats on Earnings, Growth May be Priced In
  • AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
  • Ford Stock Going Forward After Big Earnings Flop
  • 免費獲取StockNews.com關於Zimmer Biomet的研究報告(ZBH)
  • 市場回顧周-1/30-2/3
  • 細價股值得嗎？你應該投資細價股嗎？
  • Zimmer Biomet盈利節節攀升，增長可能被計入價格
  • 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
  • 福特股票在盈利大幅下滑後繼續前進

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

獲得齊默爾生物科技日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zimmer Biomet和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論